Drugs / S-337395
Trials 2
| Phase | Registry id | Dates | Indication | Sponsor | Status | Outcome |
|---|---|---|---|---|---|---|
| Phase 11 trial | ||||||
| Phase 1 | NCT06270511 | Mar → May 2024 | — | Shionogi | Completed | No outcome recorded |
| Phase 21 trial | ||||||
| Phase 2 | NCT07214571 | Dec 2025 → Dec 2026 expected | respiratory syncytial virus infectious disease | Shionogi | Recruiting | No outcome recorded |
News releases announcing trial results or a regulatory action · 2
| Date | Issuer | Release |
|---|---|---|
| 2025-01-30 | Shionogi | Results Shionogi Announces Positive Results from Phase 2 Trial of Respiratory Syncytial Virus Oral Antiviral Candidate S-337395 shionogi.com ↗ |
| 2024-10-24 | Shionogi | Regulatory Receives U.S. FDA Fast Track Designation for the Novel Anti-Respiratory Syncytial Virus Drug Candidate S-337395 shionogi.com ↗ |
All press releases naming this drug 3 releases
Evidence & citations 2 cited values
Every value below carries the sentence it was read from. 2 sources stand behind the page.
| Field | Value | Cited text |
|---|---|---|
| Known as | S-337395 | ClinicalTrials.gov intervention name — accepted as the source's own label NCT06270511 ↗ |
| Route | Oral | “Administered as an oral suspension.” NCT06270511 ↗ |